((“ovarian cancer” OR “endometrial cancer” OR “cervical cancer” OR “gynecologic cancer”) AND (“PD-1” OR “PD-L1” OR “immune checkpoint inhibitor” OR pembrolizumab OR nivolumab OR durvalumab OR dostarlimab) AND (“PARP inhibitor” OR olaparib OR niraparib OR rucaparib OR talazoparib OR veliparib)). This evidence concerns the gene PDCD1 and endometrial cancer.